Bibliography

Agar, E. (2015) “The role of cannabinoids and leptin in neurological diseases,” Acta Neurologica Scandinavica, 132(6), pp. 371–380. doi: 10.1111/ane.12411.

Andrade, C. (2016) “Cannabis and Neuropsychiatry, 1: Benefits and risks,” The Journal of Clinical Psychiatry, , pp. e551–e554. doi: 10.4088/jcp.16f10841.

Antonsdottir, I.M., Makino, K.M. and Porsteinsson, A.P. (2016) “Dazed and confused: Medical Cannabis in Alzheimer disease,” The American Journal of Geriatric Psychiatry, . doi: 10.1016/j.jagp.2016.08.015.

Beaulieu, P., Boulanger, A., Desroches, J. and Clark, A.J. (2016) “Medical cannabis: Considerations for the anesthesiologist and pain physician,” Canadian Journal of Anesthesia/Journal canadien d’anesthésie, 63(5), pp. 608–624. doi: 10.1007/s12630-016-0598-x.

Birdsall, S.M., Birdsall, T.C. and Tims, L.A. (2016) “The use of medical marijuana in cancer,” Current Oncology Reports, 18(7). doi: 10.1007/s11912-016-0530-0.

Boehnke, K.F., Litinas, E. and Clauw, D.J. (2016) “Medical Cannabis use is associated with decreased Opiate medication use in a retrospective cross-sectional survey of patients with chronic pain,” The Journal of Pain, . doi: 10.1016/j.jpain.2016.03.002.

Brierley, D.I., Samuels, J., Duncan, M., Whalley, B.J. and Williams, C.M. (2016) “Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats,” Psychopharmacology, 233(19-20), pp. 3603–3613. doi: 10.1007/s00213-016-4397-4.

Chabarria, K.C., Racusin, D.A., Antony, K.M., Kahr, M., Suter, M.A., Mastrobattista, J.M. and Aagaard, K.M. (2016) “Marijuana use and its effects in pregnancy,” American Journal of Obstetrics and Gynecology, 215(4), p. 506.e1–506.e7. doi: 10.1016/j.ajog.2016.05.044.

Clarke, R.A. and Merlin, M.D. (2014) CANNABIS: Ethnobotany and Evolution. . Berkeley: University of California Press.

Clarke, R.C. and Merlin, M.D. (2015) “Letter to the editor: Small, Ernest. 2015. Evolution and classification of Cannabis sativa (marijuana, Hemp) in relation to human utilization. Botanical review 81(3): 189-294,” The Botanical Review, 81(4), pp. 295–305. doi: 10.1007/s12229-015-9158-2.

Collier, R. (2016) “How will pot legalization affect medical marijuana?,” Canadian Medical Association Journal, 188(11), pp. 792–793. doi: 10.1503/cmaj.109-5286.

Deiana, S. (2012) “Medical use of cannabis. Cannabidiol: A new light for schizophrenia?,” Drug Testing and Analysis, 5(1), pp. 46–51. doi: 10.1002/dta.1425.

Design, W., Development and Motion, A. (2015) Major banks suddenly shunning medical marijuana companies. Available at: https://ipolitics.ca/2016/10/09/major-banks-suddenly-shunning-medical-marijuana-companies/ (Accessed: 16 October 2016).

Fasinu, P.S., Phillips, S., ElSohly, M.A. and Walker, L.A. (2016) “Current status and prospects for Cannabidiol preparations as new therapeutic agents,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 36(7), pp. 781–796. doi: 10.1002/phar.1780.

Freeman, T.P. and Winstock, A.R. (2015) “Examining the profile of high-potency cannabis and its association with severity of cannabis dependence,” Psychological Medicine, 45(15), pp. 3181–3189. doi: 10.1017/s0033291715001178.

Friedrich, J., Khatib, D., Parsa, K., Santopietro, A. and Gallicano, G.I. (2016) “The grass isn’t always greener: The effects of cannabis on embryological development,” BMC Pharmacology and Toxicology, 17(1). doi: 10.1186/s40360-016-0085-6.

Gerich, M.E., Isfort, R.W., Brimhall, B. and Siegel, C.A. (2014) “Medical marijuana for digestive disorders: High time to prescribe?,” The American Journal of Gastroenterology, 110(2), pp. 208–214. doi: 10.1038/ajg.2014.245.

Grotenhermen, F. and Müller-Vahl, K. (2012) “The Therapeutic Potential of Cannabis and Cannabinoids,” 109(29-30).

Hill, A.J., Williams, C.M., Whalley, B.J. and Stephens, G.J. (2012) “Phytocannabinoids as novel therapeutic agents in CNS disorders,” Pharmacology & Therapeutics, 133(1), pp. 79–97. doi: 10.1016/j.pharmthera.2011.09.002.

HuangWen Juan, ChenWei Wei and Zhang, X. (2016) “Endocannabinoid system: Role in depression, reward and pain control (review),” Molecular Medicine Reports, . doi: 10.3892/mmr.2016.5585.

Jiang, H., Wang, L., Merlin, M.D., Clarke, R.C., Pan, Y., Zhang, Y., Xiao, G. and Ding, X. (2016) “Ancient Cannabis Burial Shroud in a Central Eurasian Cemetery | SpringerLink,” Economic Botany, . doi: 10.1007/s12231-016-9351-1.

Kalant, H. (2016) “A critique of cannabis legalization proposals in Canada,” International Journal of Drug Policy, 34, pp. 5–10. doi: 10.1016/j.drugpo.2016.05.002.

Kermode-Scott, B. (2016) “Canadians authorised to use cannabis for medical purposes to be allowed to grow their own again,” BMJ, , p. i4480. doi: 10.1136/bmj.i4480.

Kim, H.S. and Monte, A.A. (2016) “Colorado Cannabis legalization and its effect on emergency care,” Annals of Emergency Medicine, . doi: 10.1016/j.annemergmed.2016.01.004.

Lawn, W., Freeman, T.P., Pope, R.A., Joye, A., Harvey, L., Hindocha, C., Mokrysz, C., Moss, A., Wall, M.B., Bloomfield, M.A., Das, R.K., Morgan, C.J., Nutt, D.J. and Curran, H.V. (2016) “Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: An evaluation of the cannabis ‘amotivational’ hypotheses,” Psychopharmacology, 233(19-20), pp. 3537–3552. doi: 10.1007/s00213-016-4383-x.

Lee, Y., Jo, J., Chung, H.Y., Pothoulakis, C. and Im, E. (2016) “Endocannabinoids in the gastrointestinal tract,” American Journal of Physiology - Gastrointestinal and Liver Physiology, 311(4), pp. G655–G666. doi: 10.1152/ajpgi.00294.2015.

Legleye, S., Khlat, M., Mayet, A., Beck, F., Falissard, B., Chau, N. and Peretti-Watel, P. (2016) “From cannabis initiation to daily use: Educational inequalities in consumption behaviours over three generations in France,” Addiction, 111(10), pp. 1856–1866. doi: 10.1111/add.13461.

Ligresti, A., De Petrocellis, L. and Di Marzo, V. (2016) “From Phytocannabinoids to Cannabinoid receptors and Endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology,” Physiological Reviews, 96(4), pp. 1593–1659. doi: 10.1152/physrev.00002.2016.

Lin, L.A., Ilgen, M.A., Jannausch, M. and Bohnert, K.M. (2016) “Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample,” Addictive Behaviors, 61, pp. 99–103. doi: 10.1016/j.addbeh.2016.05.015.

Lucas, P., Walsh, Z., Crosby, K., Callaway, R., Belle-Isle, L., Kay, R., Capler, R. and Holtzman, S. (2015) “Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors,” Drug and Alcohol Review, 35(3), pp. 326–333. doi: 10.1111/dar.12323.

Mizrachi Zer-Aviv, T., Segev, A. and Akirav, I. (2016) “Cannabinoids and post-traumatic stress disorder,” Behavioural Pharmacology, 27(7), pp. 561–569. doi: 10.1097/fbp.0000000000000253.

Morena, M., Patel, S., Bains, J.S. and Hill, M.N. (2015) “Neurobiological interactions between stress and the Endocannabinoid system,” Neuropsychopharmacology, 41(1), pp. 80–102. doi: 10.1038/npp.2015.166.

O’Hara, R.E., Armeli, S. and Tennen, H. (2016) “Alcohol and cannabis use among college students: Substitutes or complements?,” Addictive Behaviors, 58, pp. 1–6. doi: 10.1016/j.addbeh.2016.02.004.

Pacher, P. (2006) “The Endocannabinoid system as an emerging target of Pharmacotherapy,” Pharmacological Reviews, 58(3), pp. 389–462. doi: 10.1124/pr.58.3.2.

Palali, A. and van Ours, J.C. (2016) “Cannabis use and support for cannabis legalization,” Empirical Economics, . doi: 10.1007/s00181-016-1172-7.

Parmar, J.R., Forrest, B.D. and Freeman, R.A. (2015) “Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs,” Research in Social and Administrative Pharmacy, . doi: 10.1016/j.sapharm.2015.09.002.

Pertwee, R.G. (2015) “Endocannabinoids,” Handbook of Experimental Pharmacology, 231. doi: 10.1007/978-3-319-20825-.

Rabin, R.A., Ashare, R.L., Schnoll, R.A., Cinciripini, P.M., Hawk, L.W., Lerman, C., Tyndale, R.F. and George, T.P. (2016) “Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial,” The American Journal on Addictions, 25(4), pp. 291–296. doi: 10.1111/ajad.12382.

Rhyne, D.N., Anderson, S.L., Gedde, M. and Borgelt, L.M. (2016) “Effects of medical marijuana on migraine headache frequency in an adult population,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, , p. n/a–n/a. doi: 10.1002/phar.1673.

Rogeberg, O. and Elvik, R. (2016) “The effects of cannabis intoxication on motor vehicle collision revisited and revised,” Addiction, 111(8), pp. 1348–1359. doi: 10.1111/add.13347.

Sagar, K.A., Dahlgren, M.K., Racine, M.T., Dreman, M.W., Olson, D.P. and Gruber, S.A. (2016) “Joint effects: A pilot investigation of the impact of Bipolar disorder and marijuana use on cognitive function and mood,” PLOS ONE, 11(6), p. e0157060. doi: 10.1371/journal.pone.0157060.

Savage, S.R., Romero-Sandoval, A., Schatman, M., Wallace, M., Fanciullo, G., McCarberg, B. and Ware, M. (2016) “Cannabis in pain treatment: Clinical and research considerations,” The Journal of Pain, . doi: 10.1016/j.jpain.2016.02.007.

Scherma, M., Muntoni, A.L., Melis, M., Fattore, L., Fadda, P., Fratta, W. and Pistis, M. (2016) “Interactions between the endocannabinoid and nicotinic cholinergic systems: Preclinical evidence and therapeutic perspectives,” Psychopharmacology, 233(10), pp. 1765–1777. doi: 10.1007/s00213-015-4196-3.

Small, E. (2015) “Evolution and classification of Cannabis sativa (marijuana, Hemp) in relation to human utilization,” The Botanical Review, 81(3), pp. 189–294. doi: 10.1007/s12229-015-9157-3.

Stringer, R.J. and Maggard, S.R. (2016) “Reefer madness to marijuana legalization: Media exposure and American attitudes toward marijuana (1975-2012),” Journal of Drug Issues, 46(4), pp. 428–445. doi: 10.1177/0022042616659762.

Temple, L.M. (2016) “Medical marijuana and pain management,” Disease-a-Month, 62(9), pp. 346–352. doi: 10.1016/j.disamonth.2016.05.014.

Understanding the New Access to Cannabis for Medical Purposes Regulations (2016) Available at: http://healthycanadians.gc.ca/publications/drugs-products-medicaments-produits/understanding-regulations-medical-cannabis-medicales-comprehension-reglements/index-eng.php (Accessed: 13 October 2016).

Wargent, E.T., Zaibi, M.S., Silvestri, C., Hislop, D.C., Stocker, C.J., Stott, C.G., Guy, G.W., Duncan, M., Di Marzo, V. and Cawthorne, M.A. (2013) “The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity,” Nutrition & Diabetes, 3(5), p. e68. doi: 10.1038/nutd.2013.9.

Waterreus, A., Di Prinzio, P., Watts, G.F., Castle, D., Galletly, C. and Morgan, V.A. (2016) “Metabolic syndrome in people with a psychotic illness: Is cannabis protective?,” Psychological Medicine, 46(08), pp. 1651–1662. doi: 10.1017/s0033291715002883.

Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V., Keurentjes, J.C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M. and Kleijnen, J. (2015) “Cannabinoids for medical use,” JAMA, 313(24), p. 2456. doi: 10.1001/jama.2015.6358.

WIlliams , J., Van Ours, J.C. and Grossman, M. (no date) “‘Users have a greater awareness of cannabis not being as harmful as abstainers think it is,’” Health Economics, 25.

Williams, J., van Ours, J.C. and Grossman, M. (2016) “Attitudes to legalizing cannabis use,” Health Economics, , p. n/a–n/a. doi: 10.1002/hec.3340.